ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction.

ABSTRACT:

Aims

This study aimed to compare the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) therapy with angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy for cardiovascular outcomes in patients with acute myocardial infarction (AMI).

Methods and results

Data were collected from the Biobank of the First Affiliated Hospital of Xi'an Jiaotong University between January 2016 and December 2020. A total of 7556 AMI patients were screened for eligibility. Propensity score matching based on age, sex, blood pressure, kidney function, baseline left ventricular ejection fraction (LVEF), and cardiovascular medication were conducted, resulting in 291 patients with AMI being assigned to ARNI, ACEI, and ARB group, respectively. Patients recei

SUBMITTER: She J 

PROVIDER: S-EPMC8712820 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature